312 related articles for article (PubMed ID: 32317181)
21. The Diverse Genomic Landscape of Clinically Low-risk Prostate Cancer.
Cooperberg MR; Erho N; Chan JM; Feng FY; Fishbane N; Zhao SG; Simko JP; Cowan JE; Lehrer J; Alshalalfa M; Kolisnik T; Chelliserry J; Margrave J; Aranes M; Plessis MD; Buerki C; Tenggara I; Davicioni E; Carroll PR
Eur Urol; 2018 Oct; 74(4):444-452. PubMed ID: 29853306
[TBL] [Abstract][Full Text] [Related]
22. CRISPR screening identifies CDK12 as a conservative vulnerability of prostate cancer.
Lei H; Wang Z; Jiang D; Liu F; Liu M; Lei X; Yang Y; He B; Yan M; Huang H; Liu Q; Pang J
Cell Death Dis; 2021 Jul; 12(8):740. PubMed ID: 34315855
[TBL] [Abstract][Full Text] [Related]
23. Single-Cell Circulating Tumor Cell Analysis Reveals Genomic Instability as a Distinctive Feature of Aggressive Prostate Cancer.
Malihi PD; Graf RP; Rodriguez A; Ramesh N; Lee J; Sutton R; Jiles R; Ruiz Velasco C; Sei E; Kolatkar A; Logothetis C; Navin NE; Corn P; Aparicio AM; Dittamore R; Hicks J; Kuhn P; Zurita AJ
Clin Cancer Res; 2020 Aug; 26(15):4143-4153. PubMed ID: 32341031
[TBL] [Abstract][Full Text] [Related]
24. Comprehensive genomic profiling testing in Japanese castration-resistant prostate cancer patients: results of a single-center retrospective cohort study.
Fukushima T; Goto K; Hayashi T; Ikeda K; Hatayama T; Yamanaka R; Iwane K; Tasaka R; Kohada Y; Takemoto K; Kobatake K; Goriki A; Toshida A; Nakahara H; Motonaga M; Tokumo K; Fujii Y; Hayes CN; Okamoto W; Kubo T; Matsumoto T; Shiota M; Yamamoto N; Urabe Y; Hiyama E; Arihiro K; Hinoi T; Hinata N
Jpn J Clin Oncol; 2024 Feb; 54(2):175-181. PubMed ID: 37899139
[TBL] [Abstract][Full Text] [Related]
25. Genomic Analysis of Localized High-Risk Prostate Cancer Circulating Tumor Cells at the Single-Cell Level.
Rangel-Pozzo A; Liu S; Wajnberg G; Wang X; Ouellette RJ; Hicks GG; Drachenberg D; Mai S
Cells; 2020 Aug; 9(8):. PubMed ID: 32784507
[TBL] [Abstract][Full Text] [Related]
26. CDK12 and HER2 coamplification in two urothelial carcinomas with rapid and aggressive clinical progression.
Yanai Y; Kosaka T; Nakamura K; Aimono E; Matsumoto K; Morita S; Mikami S; Nishihara H; Oya M
Cancer Sci; 2020 Dec; 111(12):4652-4655. PubMed ID: 33038052
[TBL] [Abstract][Full Text] [Related]
27. A novel germline EGFR variant p.R831H causes predisposition to familial CDK12-mutant prostate cancer with tandem duplicator phenotype.
Qian K; Wang G; Ju L; Liu J; Luo Y; Wang Y; Peng T; Chen F; Zhang Y; Xiao Y; Wang X
Oncogene; 2020 Oct; 39(44):6871-6878. PubMed ID: 32978518
[TBL] [Abstract][Full Text] [Related]
28. Targeted Next-Generation Sequencing Reveals Heterogenous Genomic Features in Viscerally Metastatic Prostate Cancer.
Gong Y; Fan L; Fei X; Zhu Y; Du X; He Y; Pan J; Dong B; Xue W
J Urol; 2021 Aug; 206(2):279-288. PubMed ID: 33780283
[TBL] [Abstract][Full Text] [Related]
29. Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer.
Quigley DA; Dang HX; Zhao SG; Lloyd P; Aggarwal R; Alumkal JJ; Foye A; Kothari V; Perry MD; Bailey AM; Playdle D; Barnard TJ; Zhang L; Zhang J; Youngren JF; Cieslik MP; Parolia A; Beer TM; Thomas G; Chi KN; Gleave M; Lack NA; Zoubeidi A; Reiter RE; Rettig MB; Witte O; Ryan CJ; Fong L; Kim W; Friedlander T; Chou J; Li H; Das R; Li H; Moussavi-Baygi R; Goodarzi H; Gilbert LA; Lara PN; Evans CP; Goldstein TC; Stuart JM; Tomlins SA; Spratt DE; Cheetham RK; Cheng DT; Farh K; Gehring JS; Hakenberg J; Liao A; Febbo PG; Shon J; Sickler B; Batzoglou S; Knudsen KE; He HH; Huang J; Wyatt AW; Dehm SM; Ashworth A; Chinnaiyan AM; Maher CA; Small EJ; Feng FY
Cell; 2018 Jul; 174(3):758-769.e9. PubMed ID: 30033370
[TBL] [Abstract][Full Text] [Related]
30. Structural Alterations Driving Castration-Resistant Prostate Cancer Revealed by Linked-Read Genome Sequencing.
Viswanathan SR; Ha G; Hoff AM; Wala JA; Carrot-Zhang J; Whelan CW; Haradhvala NJ; Freeman SS; Reed SC; Rhoades J; Polak P; Cipicchio M; Wankowicz SA; Wong A; Kamath T; Zhang Z; Gydush GJ; Rotem D; ; Love JC; Getz G; Gabriel S; Zhang CZ; Dehm SM; Nelson PS; Van Allen EM; Choudhury AD; Adalsteinsson VA; Beroukhim R; Taplin ME; Meyerson M
Cell; 2018 Jul; 174(2):433-447.e19. PubMed ID: 29909985
[TBL] [Abstract][Full Text] [Related]
31. CDK12 inactivation across solid tumors: an actionable genetic subtype.
Marshall CH; Imada EL; Tang Z; Marchionni L; Antonarakis ES
Oncoscience; 2019 May; 6(5-6):312-316. PubMed ID: 31360735
[TBL] [Abstract][Full Text] [Related]
32.
Antonarakis ES; Isaacsson Velho P; Fu W; Wang H; Agarwal N; Sacristan Santos V; Maughan BL; Pili R; Adra N; Sternberg CN; Vlachostergios PJ; Tagawa ST; Bryce AH; McNatty AL; Reichert ZR; Dreicer R; Sartor O; Lotan TL; Hussain M
JCO Precis Oncol; 2020; 4():370-381. PubMed ID: 32462107
[TBL] [Abstract][Full Text] [Related]
33. Genomic Profiling of Prostate Cancers from Men with African and European Ancestry.
Koga Y; Song H; Chalmers ZR; Newberg J; Kim E; Carrot-Zhang J; Piou D; Polak P; Abdulkadir SA; Ziv E; Meyerson M; Frampton GM; Campbell JD; Huang FW
Clin Cancer Res; 2020 Sep; 26(17):4651-4660. PubMed ID: 32651179
[TBL] [Abstract][Full Text] [Related]
34. Quantitative Mass Spectrometry to Interrogate Proteomic Heterogeneity in Metastatic Lung Adenocarcinoma and Validate a Novel Somatic Mutation CDK12-G879V.
Zhang X; Nguyen KD; Rudnick PA; Roper N; Kawaler E; Maity TK; Awasthi S; Gao S; Biswas R; Venugopalan A; Cultraro CM; Fenyö D; Guha U
Mol Cell Proteomics; 2019 Apr; 18(4):622-641. PubMed ID: 30617155
[TBL] [Abstract][Full Text] [Related]
35. The Impact of PIK3R1 Mutations and Insulin-PI3K-Glycolytic Pathway Regulation in Prostate Cancer.
Chakraborty G; Nandakumar S; Hirani R; Nguyen B; Stopsack KH; Kreitzer C; Rajanala SH; Ghale R; Mazzu YZ; Pillarsetty NVK; Lee GM; Scher HI; Morris MJ; Traina T; Razavi P; Abida W; Durack JC; Solomon SB; Vander Heiden MG; Mucci LA; Wibmer AG; Schultz N; Kantoff PW
Clin Cancer Res; 2022 Aug; 28(16):3603-3617. PubMed ID: 35670774
[TBL] [Abstract][Full Text] [Related]
36. Genomic Alterations in Cell-Free DNA and Enzalutamide Resistance in Castration-Resistant Prostate Cancer.
Wyatt AW; Azad AA; Volik SV; Annala M; Beja K; McConeghy B; Haegert A; Warner EW; Mo F; Brahmbhatt S; Shukin R; Le Bihan S; Gleave ME; Nykter M; Collins CC; Chi KN
JAMA Oncol; 2016 Dec; 2(12):1598-1606. PubMed ID: 27148695
[TBL] [Abstract][Full Text] [Related]
37. Integrative Genomic Analysis of Coincident Cancer Foci Implicates CTNNB1 and PTEN Alterations in Ductal Prostate Cancer.
Gillard M; Lack J; Pontier A; Gandla D; Hatcher D; Sowalsky AG; Rodriguez-Nieves J; Vander Griend D; Paner G; VanderWeele D
Eur Urol Focus; 2019 May; 5(3):433-442. PubMed ID: 29229583
[TBL] [Abstract][Full Text] [Related]
38. Multifocal Primary Prostate Cancer Exhibits High Degree of Genomic Heterogeneity.
Løvf M; Zhao S; Axcrona U; Johannessen B; Bakken AC; Carm KT; Hoff AM; Myklebost O; Meza-Zepeda LA; Lie AK; Axcrona K; Lothe RA; Skotheim RI
Eur Urol; 2019 Mar; 75(3):498-505. PubMed ID: 30181068
[TBL] [Abstract][Full Text] [Related]
39.
Lotan TL; Antonarakis ES
Clin Cancer Res; 2021 Jan; 27(2):380-382. PubMed ID: 33199495
[TBL] [Abstract][Full Text] [Related]
40. Genomic Features of Muscle-invasive Bladder Cancer Arising After Prostate Radiotherapy.
Mossanen M; Carvalho FLF; Muralidhar V; Preston MA; Reardon B; Conway JR; Curran C; Freeman D; Sha S; Sonpavde G; Hirsch M; Kibel AS; Van Allen EM; Mouw KW
Eur Urol; 2022 May; 81(5):466-473. PubMed ID: 34953602
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]